Karyopharm Therapeutics (KPTI) Gets a Buy from Piper Sandler
TipRanks (Mon, 22-Apr 8:33 AM ET)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Mon, 1-Apr 4:05 PM ET)
Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO (selinexor)
Business Wire (Wed, 13-Mar 4:35 PM ET)
PRNewswire (Wed, 6-Mar 4:05 PM ET)
PRNewswire (Thu, 29-Feb 7:30 AM ET)
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
PRNewswire (Thu, 22-Feb 7:00 AM ET)
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Karyopharm Therapeutics trades on the NASDAQ stock market under the symbol KPTI.
As of April 23, 2024, KPTI stock price declined to $1.09 with 1,574,643 million shares trading.
KPTI has a beta of 1.58, meaning it tends to be more sensitive to market movements. KPTI has a correlation of 0.06 to the broad based SPY ETF.
KPTI has a market cap of $126.95 million. This is considered a Micro Cap stock.
Last quarter Karyopharm Therapeutics reported $34 million in Revenue and -$.36 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.05.
In the last 3 years, KPTI stock traded as high as $14.73 and as low as $.62.
The top ETF exchange traded funds that KPTI belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
KPTI has underperformed the market in the last year with a price return of -73.3% while the SPY ETF gained +24.3%. However, in the short term, KPTI had mixed performance relative to the market. It has outperformed in the last 3 months, returning +31.1% vs +4.9% return in SPY. But in the last 2 weeks, KPTI shares have been beat by the market, returning -19.3% compared to an SPY return of -2.5%.
KPTI support price is $1.05 and resistance is $1.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KPTI stock will trade within this expected range on the day.